The First Cancer ETF Tracks the Hottest Area of Biotech
Biotech investor Brad Loncar zeroes in on immunotherapies with a new fund.
This article is for subscribers only.
Launching a biotech exchange-traded fund after a big selloff in the sector isn’t the best timing. But Brad Loncar, a popular biotech blogger and investor, hopes people will be intrigued by the very specific and very hot slice of the biotech sector his new ETF focuses on—cancer immunotherapies.
The Loncar Cancer Immunotherapy ETF (CNCR), which comes out on Wednesday, invests in companies that treat cancer by using drugs that modify the body’s immune response so it goes after solid tumors like melanoma or lung cancer, or that alter immune cells to combat blood malignancies.